title: Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial.
abstract: OBJECTIVE
  Restenosis is higher among certain subpopulations when subjected to percutaneous coronary interventions even when using drug-eluting stents. The randomised SPIRIT II trial demonstrated the superiority of the XIENCE V Everolimus Eluting Coronary Stent System over the TAXUS Paclitaxel-Eluting Stent System in terms of in-stent late loss at six months among 300 patients treated for de novo native coronary artery lesions.
  
  
  RESULTS
  In this post-hoc analysis of SPIRIT II we focused on six-month angiographic outcomes of diabetic patients (n=69), left anterior descending arteries (n=149), long lesions >20 mm (n=43), small vessels <3.0 mm (n=209) and type B2 and C lesions (n=233). In-stent late loss was consistently less among all subgroups when treated by everolimus-eluting stents compared to paclitaxel-eluting stents: diabetics 0.15+/-0.26 mm versus 0.39+/-0.34 mm, p=0.006; LAD 0.12+/-0.23 mm versus 0.44+/-0.37 mm, p<0.001; long lesions 0.13+/-0.26 mm versus 0.43+/-0.46 mm, p=0.070; small vessels 0.17+/-0.28 mm versus 0.37+/-0.39 mm, p<0.001; B2/C lesions 0.12+/-0.31 mm versus 0.36+/-0.36 mm, p<0.001.
  
  
  CONCLUSIONS
  The everolimus-eluting stent remained superior in terms of in-stent late loss in a variety of higher risk populations for restenosis compared to the paclitaxel-eluting stent. These analyses were consistent with the in-stent late loss results of the overall SPIRIT II trial population.
authors.affiliation: Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH (Academic Teaching Hospital of the University of Kiel), Bad Segeberg, Germany.
authors.forename: Ahmed A
authors.initials: AA
authors.lastname: Khattab
authors.forename: Gert
authors.initials: G
authors.lastname: Richardt
authors.forename: Vitali
authors.initials: V
authors.lastname: Verin
authors.forename: Henning
authors.initials: H
authors.lastname: Kelbaek
authors.forename: Carlos
authors.initials: C
authors.lastname: Macaya
authors.forename: Jacques
authors.initials: J
authors.lastname: Berland
authors.forename: Karine
authors.initials: K
authors.lastname: Miquel-Hebert
authors.forename: Cécile
authors.initials: C
authors.lastname: Dorange
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys